[Exchange & Cooperation] Joining Hands to Explore a New Future in Cell Therapy: Mutual Learning to Drive Industry Development

On July 16, 2025, a delegation led by Zhong Fuping, Director of the Construction Service Center of Wuhan National Bio-industry Base; Li Chunlong, Deputy Director of the Science and Technology Innovation Bureau of East Lake High-tech Zone; Miao Yun, Deputy Director of the Industry Division at the Construction Service Center of Wuhan National Bio-industry Base; Zhang Kehao, Section Chief of the Organization Department of East Lake High-tech Zone; Zhang Hanrui, Vice President of Wuhan Institute of Biotechnology; Huang Liwei, Chairman of Wuhan Optics Valley Bio-industry Base Construction Investment Co., Ltd.; and Gao Xianhui, Senior Supervisor of the Hubei Bioeconomy Research Center, visited Deep Harbour Cell Valley for exchange and inspection. They were warmly received by Shi Yuanyuan, Founder of Deep Harbour Cell Valley; Fu Yuchen, Assistant to the Chairman; Li Weiwei, Vice Chairman (Designate) of Deep Harbour Cell Valley’s Wuhan Subsidiary; and General Manager Li Qi. The two sides engaged in in-depth discussions on technological innovation, industrial translation, and regional cooperation in the field of cell and gene therapy.

Accompanied by Shi Yuanyuan, the delegation toured the Smart Exhibition Hall and the multi-site linked laboratory monitoring dashboard at Deep Harbour Cell Valley. Detailed introductions were provided regarding the group’s whole-industry-chain layout—from laboratory R&D to clinical application—as well as its development history, core technologies, and strategic planning. Breakthrough achievements in cell therapy were showcased. The visiting leaders spoke highly of Deep Harbour Cell Valley’s outstanding accomplishments in technological innovation and industrial application.

During the symposium, both parties held pragmatic discussions focusing on the “bottleneck” issues hindering the development of the cell therapy industry. Shi Yuanyuan shared Deep Harbour Cell Valley’s progress in new drug development and clinical research collaboration, proposing a cooperative initiative of “Technology Sharing + Regional Linkage.” Looking ahead, the Cell Valley Group plans to establish a company in Wuhan. This strategic layout will fully leverage the group’s accumulated core technological advantages in cell and gene therapy, injecting strong momentum into the high-quality development of Wuhan’s biopharmaceutical industry. Furthermore, it will accelerate the clinical translation of cell therapy technologies, ultimately benefiting a broad patient population.

Zhong Fuping noted that the Wuhan National Bio-industry Base is one of the top ten biopharmaceutical industrial parks in China, boasting a comprehensive biopharmaceutical industry chain in Optics Valley, East Lake High-tech Zone. He expressed expectations to deepen synergy with Deep Harbour Cell Valley in areas such as sharing clinical resources, implementing policy pilots, and cooperating on industrial funds, jointly promoting the journey of cell therapy technologies from the laboratory to patients.

This visit and exchange built a bridge for cooperation between Deep Harbour Cell Valley, the Wuhan National Bio-industry Base, and other relevant entities. In the future, Deep Harbour Cell Valley will continue to open up its core technology platforms, unite advantageous resources in Wuhan and other regions, and explore the model of a “Cross-Regional Cell Therapy Innovation Consortium” to accelerate the translation and application of breakthrough therapies.